Posts

FDA grants breakthrough therapy status to Arrowhead’s p...

The US FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuti...

GSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial

After successfully completing two trials, SWIFT-1 and SWIFT-2, for its long-acti...

CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihoo...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

Sildenafil citrate by XOMA Royalty for Female Hypoactiv...

Sildenafil citrate is under clinical development by XOMA Royalty and currently i...

CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Li...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Follicular Lymphoma: Likelihood...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymp...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Primary Mediastinal B-Cell Lymp...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Refractory Chronic Lymphocytic ...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Relapsed Chronic Lymphocytic Le...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

Investment opportunities in atopic dermatitis may drive...

The atopic dermatitis market is facing increased growth, with a projected market...

Men taking valproate and their partners warned to use c...

A study suggests that children may face a higher risk of harm if their father is...

GSK’s asthma blockbuster Nucala secures win in COPD Pha...

GSK is adding more strings to Nucala’s bow as the drug’s sales continue to grow.

FDA grants ODD to Abdera’s neuroendocrine carcinoma tre...

The US FDA has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD...